XTX Topco Ltd Purchases New Shares in Pulmonx Co. (NASDAQ:LUNG)

XTX Topco Ltd purchased a new position in Pulmonx Co. (NASDAQ:LUNG) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 34,968 shares of the company’s stock, valued at approximately $222,000. XTX Topco Ltd owned about 0.09% of Pulmonx as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Sei Investments Co. boosted its stake in shares of Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after purchasing an additional 1,800 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock valued at $6,714,000 after buying an additional 69,595 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Pulmonx by 1.0% in the second quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock worth $5,289,000 after buying an additional 8,004 shares during the period. Vanguard Group Inc. lifted its stake in shares of Pulmonx by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock worth $19,262,000 after acquiring an additional 11,417 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock valued at $79,000 after acquiring an additional 7,316 shares during the period. Institutional investors own 91.04% of the company’s stock.

Insiders Place Their Bets

In other news, Director Glendon E. French III sold 20,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $8.09, for a total value of $161,800.00. Following the sale, the director now directly owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Pulmonx news, insider Geoffrey Beran Rose sold 4,586 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total value of $30,726.20. Following the sale, the insider now owns 295,433 shares in the company, valued at approximately $1,979,401.10. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $8.09, for a total transaction of $161,800.00. Following the sale, the director now directly owns 1,111,974 shares in the company, valued at approximately $8,995,869.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,351 shares of company stock valued at $231,094. 5.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on LUNG shares. Canaccord Genuity Group upped their price target on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Lake Street Capital initiated coverage on shares of Pulmonx in a research report on Tuesday, June 4th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Wells Fargo & Company lowered their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.83.

Pulmonx Price Performance

Shares of LUNG opened at $8.29 on Monday. The firm has a market capitalization of $321.78 million, a PE ratio of -5.38 and a beta of 0.63. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92. The company’s fifty day moving average price is $7.27 and its 200-day moving average price is $7.58. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. The business had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. On average, equities research analysts predict that Pulmonx Co. will post -1.64 EPS for the current year.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.